Additionally, in the same study, it was observed that anti-VEGF therapy jeopardizes the immune landscape of the tumor, through the increased transcription from the SLC7A11 gene encoding the glutamate/cystine antiporter and increased extracellular glutamate production promoting Treg activation and CD8+ T cell suppression. The gene discussed is VEGFA; the disease is neoplasm.